CONTEXT: The relationship of fibroblast growth factor 21 (FGF21) with glucose metabolism and insulin resistance has not been well characterized in community-dwelling adults. OBJECTIVE: The objective of the study was to examine the relationship of FGF21 with glucose metabolism and insulin resistance. DESIGN: Serum FGF21, fasting plasma glucose (FPG), glucose tolerance, and insulin resistance were measured in a cross-sectional study, 2002-2007. SETTING: The study was the Baltimore Longitudinal Study of Aging, a natural history cohort study of aging in community-dwelling men and women. PARTICIPANTS: Seven hundred adults, mean age 63.3 yr, participated in the study. MAIN OUTCOME MEASURES: FPG, 2-h plasma glucose, homeostasis model of insulin resistance, whole-body insulin sensitivity (Matsuda index), glucose area under the curve (AUC), and insulin AUC were measured. RESULTS: Overall, the median (25th and 75th percentiles) FGF21 concentration was 225 (126, 370) pg/ml. The proportion of adults with normal, impaired, and diabetic FPG was 77.0, 21.4, and 1.6%, and those with normal, impaired, and diabetic 2-h plasma glucose was 76.7, 19.1, and 4.1%, respectively. Log serum FGF21 (picograms per milliliter), per 1 sd increase, was associated with an FPG (odds ratio 1.43, 95% confidence interval 1.15, 1.77, P = 0.001) and with 2-h plasma glucose (odds ratio 1.39, 95% confidence interval 1.12, 1.73, P = 0.003), in respective multivariate, ordered logistic regression models, adjusted for potential confounders. Serum FGF21 (picograms per milliliter) was associated with the homeostasis model of insulin resistance, the Matsuda index, glucose AUC, and insulin AUC (all P < 0.0001) in respective multivariable linear regression models adjusted for potential confounders. CONCLUSIONS: Higher serum FGF21 concentrations were associated with abnormal glucose metabolism and insulin resistance in community-dwelling adults.
CONTEXT: The relationship of fibroblast growth factor 21 (FGF21) with glucose metabolism and insulin resistance has not been well characterized in community-dwelling adults. OBJECTIVE: The objective of the study was to examine the relationship of FGF21 with glucose metabolism and insulin resistance. DESIGN: Serum FGF21, fasting plasma glucose (FPG), glucose tolerance, and insulin resistance were measured in a cross-sectional study, 2002-2007. SETTING: The study was the Baltimore Longitudinal Study of Aging, a natural history cohort study of aging in community-dwelling men and women. PARTICIPANTS: Seven hundred adults, mean age 63.3 yr, participated in the study. MAIN OUTCOME MEASURES: FPG, 2-h plasma glucose, homeostasis model of insulin resistance, whole-body insulin sensitivity (Matsuda index), glucose area under the curve (AUC), and insulin AUC were measured. RESULTS: Overall, the median (25th and 75th percentiles) FGF21 concentration was 225 (126, 370) pg/ml. The proportion of adults with normal, impaired, and diabetic FPG was 77.0, 21.4, and 1.6%, and those with normal, impaired, and diabetic 2-h plasma glucose was 76.7, 19.1, and 4.1%, respectively. Log serum FGF21 (picograms per milliliter), per 1 sd increase, was associated with an FPG (odds ratio 1.43, 95% confidence interval 1.15, 1.77, P = 0.001) and with 2-h plasma glucose (odds ratio 1.39, 95% confidence interval 1.12, 1.73, P = 0.003), in respective multivariate, ordered logistic regression models, adjusted for potential confounders. Serum FGF21 (picograms per milliliter) was associated with the homeostasis model of insulin resistance, the Matsuda index, glucose AUC, and insulin AUC (all P < 0.0001) in respective multivariable linear regression models adjusted for potential confounders. CONCLUSIONS: Higher serum FGF21 concentrations were associated with abnormal glucose metabolism and insulin resistance in community-dwelling adults.
Authors: Saul Genuth; K G M M Alberti; Peter Bennett; John Buse; Ralph Defronzo; Richard Kahn; John Kitzmiller; William C Knowler; Harold Lebovitz; Ake Lernmark; David Nathan; Jerry Palmer; Robert Rizza; Christopher Saudek; Jonathan Shaw; Michael Steffes; Michael Stern; Jaako Tuomilehto; Paul Zimmet Journal: Diabetes Care Date: 2003-11 Impact factor: 19.112
Authors: Rita R Kalyani; E Jeffrey Metter; Ramona Ramachandran; Chee W Chia; Christopher D Saudek; Luigi Ferrucci Journal: J Gerontol A Biol Sci Med Sci Date: 2011-02-24 Impact factor: 6.053
Authors: Alexei Kharitonenkov; Tatiyana L Shiyanova; Anja Koester; Amy M Ford; Radmila Micanovic; Elizabeth J Galbreath; George E Sandusky; Lisa J Hammond; Julie S Moyers; Rebecca A Owens; Jesper Gromada; Joseph T Brozinick; Eric D Hawkins; Victor J Wroblewski; De-Shan Li; Farrokh Mehrbod; S Richard Jaskunas; Armen B Shanafelt Journal: J Clin Invest Date: 2005-05-02 Impact factor: 14.808
Authors: Yasushi Ogawa; Hiroshi Kurosu; Masaya Yamamoto; Animesh Nandi; Kevin P Rosenblatt; Regina Goetz; Anna V Eliseenkova; Moosa Mohammadi; Makoto Kuro-o Journal: Proc Natl Acad Sci U S A Date: 2007-04-23 Impact factor: 11.205
Authors: Ja Young Jeon; Sung-E Choi; Eun Suk Ha; Tae Ho Kim; Jong Gab Jung; Seung Jin Han; Hae Jin Kim; Dae Jung Kim; Yup Kang; Kwan-Woo Lee Journal: Endocrine Date: 2016-01-12 Impact factor: 3.633
Authors: Melissa M Markofski; Kristofer Jennings; Chad Dolan; Natalie A Davies; Emily C LaVoy; Edward J Ryan; Andres E Carrillo Journal: Am J Lifestyle Med Date: 2019-08-02
Authors: Valentina Emmanuele; Jaya Ganesh; Georgirene Vladutiu; Richard Haas; Douglas Kerr; Russell P Saneto; Bruce H Cohen; Johan L K Van Hove; Fernando Scaglia; Charles Hoppel; Xiomara Q Rosales; Emanuele Barca; Richard Buchsbaum; John L Thompson; Salvatore DiMauro; Michio Hirano Journal: Mol Genet Metab Date: 2022-05-13 Impact factor: 4.204
Authors: Y Panahi; S Bonakdaran; M A Yaghoubi; M R Keramati; M Haratian; A Sahebkar Journal: Acta Endocrinol (Buchar) Date: 2016 Jul-Sep Impact factor: 0.877